Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Thoru Pederson
As of late, the rate of gynecological threatening growths during pregnancy has expanded, essentially because of the expanded number of advanced age pregnancy. The most widely recognized gynecological threatening growths in pregnancy are cervical disease, representing 71.6%, trailed by ovarian harmful cancers, representing 7.0%. The frequency of cervical malignant growth in pregnancy is itself not exceptionally high, and the side effects are effectively mistaken for different sicknesses in pregnancy. During pregnancy, gynecological assessment is restricted, and consequently, the pace of misdiagnosis is higher. The therapy of cervical malignant growth during pregnancy is connected with many elements, for example, cancer size, obsessive sort, time of development, lymph hub association, and patients' ability to keep up with pregnancy. As an explanation of these variables, deciding the ideal treatment is troublesome. This article surveys the examination progress on the conclusion and therapy standards of cervical disease in pregnancy, to figure out some kind of harmony between powerful treatment of cancers and assurance of fetal wellbeing and stay away from defers in therapy and preterm conveyance.